Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory …
PURPOSE Although chimeric antigen receptor T therapy (CAR-T) cells are an established
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …
[HTML][HTML] Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease
H Deng, M Liu, T Yuan, H Zhang, R Cui, J Li… - Frontiers in …, 2021 - frontiersin.org
In recent years, many new treatments for relapsed/refractory (R/R) multiple myeloma (MM)
have improved patient prognosis, but the prognosis of patients with extramedullary MM is …
have improved patient prognosis, but the prognosis of patients with extramedullary MM is …
[HTML][HTML] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
G Roex, M Timmers, K Wouters… - Journal of hematology & …, 2020 - Springer
Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-
cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic …
cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic …